Inivata appoints Jacqui Watson as Chief People Officer

Research Triangle Park, NC, USA and Cambridge, UK, August 12, 2019 — Inivata, a leader in liquid biopsy, is pleased to announce the appointment of Jacqui Watson as Chief People Officer.

Jacqui has an extensive background of working internationally as an HR Director, people developer and consultant within various organizations at a senior level, spanning over 20 years and covering various sectors including pharma, IT and hospitality.

Throughout her career Jacqui has focused on inspiring individuals and teams to reach their full potential. She was most recently consulting for various companies, where her primary focus was to identify and develop a sustainable supply of leadership and talent from within these organizations.

Clive Morris, Chief Executive Officer at Inivata, said: “Jacqui brings a wealth of experience to the Inivata team and her expertise will be invaluable as we continue to grow the business to support the commercialization of our lead product and advance our exciting portfolio of future assets.”

Jacqui Watson, Chief People Officer at Inivata, said: “I have been hugely impressed by the caliber and dedication of the team here at Inivata and I’m excited to support the Company’s continued growth, through the attraction of new talent and the development of our current very talented people. I am looking forward to working alongside the team as the company works to transform the lives of cancer patients.”

About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US)

inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271

 

Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News